Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
November 07, 2023 07:30 ET
|
Adaptive Biotechnologies
Data generated by Adaptive’s next-generation sequencing-based MRD assay will support the development and commercialization of investigational medicines for hematologic malignancies SEATTLE, Nov. 07,...
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023
November 02, 2023 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Announces Launch of Epic Integration for clonoSEQ®
September 13, 2023 07:30 ET
|
Adaptive Biotechnologies
SEATTLE, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 30, 2023 16:30 ET
|
Adaptive Biotechnologies
SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results
August 02, 2023 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023
July 10, 2023 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, July 10, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
June 02, 2023 07:34 ET
|
Adaptive Biotechnologies
New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with hematologic cancers clonoSEQ continues to be the MRD test of...
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
May 24, 2023 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, May 24, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
May 12, 2023 08:00 ET
|
Adaptive Biotechnologies
SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
May 09, 2023 07:30 ET
|
Adaptive Biotechnologies
SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...